Skip to content

ZYNERBA PHARMACEUTICALS, INC.: 10-Q filed 2018-08-02

What ZYNERBA PHARMACEUTICALS, INC. reported in its quarterly report filed 2018-08-02 (fiscal Q2 2018): 33 published measures, 79 facts as tagged in accession 0001558370-18-006158.

This filing

Form
10-Q (quarterly report)
Filed
2018-08-02
Fiscal period
fiscal Q2 2018
Accession
0001558370-18-006158 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ZYNERBA PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2018-06-3052,203,546USD
At 2017-12-3169,054,309USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2018-06-3012,124,642USD
At 2017-12-318,104,721USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2018-06-3040,078,904USD
At 2017-12-3160,949,588USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2018-06-3043,115,051USD
At 2017-12-3162,510,277USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2018-01-01 to 2018-06-30-24,313,567USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2018-01-01 to 2018-06-30-19,277,655USD181
2017-01-01 to 2017-06-30-15,321,430USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2018-01-01 to 2018-06-30117,571USD181
2017-01-01 to 2017-06-3078,207USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2017-01-01 to 2017-06-3054,613,045USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2018-01-01 to 2018-06-30-117,571USD181
2017-01-01 to 2017-06-30-78,207USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2018-06-30-102,294,433USD
At 2017-12-31-77,980,866USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2018-06-30273,784USD
At 2017-12-31164,527USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2018-01-01 to 2018-06-303,442,883USD181
2017-01-01 to 2017-06-302,544,073USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2018-04-01 to 2018-06-30-11,969,806USD91
2018-01-01 to 2018-06-30-24,365,942USD181
2017-04-01 to 2017-06-30-8,365,654USD91
2017-01-01 to 2017-06-30-16,068,902USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2018-06-3049,039,090USD
At 2017-12-3168,227,582USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2018-06-3011,290,668USD
At 2017-12-317,442,721USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2018-06-306,379,750USD
At 2017-12-313,355,255USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2018-04-01 to 2018-06-3011,969,806USD91
2018-01-01 to 2018-06-3024,365,942USD181
2017-04-01 to 2017-06-308,365,654USD91
2017-01-01 to 2017-06-3016,068,902USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2018-04-01 to 2018-06-308,533,466USD91
2018-01-01 to 2018-06-3017,508,979USD181
2017-04-01 to 2017-06-305,732,797USD91
2017-01-01 to 2017-06-3011,224,252USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2018-06-3013,561,373shares
At 2017-12-3113,553,873shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2018-06-3043,115,051USD
At 2017-12-3162,510,277USD
At 2017-06-3070,179,199USD
At 2016-12-3130,965,791USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2018-06-30142,359,776USD
At 2017-12-31138,916,900USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2018-06-30485,024USD
At 2017-12-31327,615USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2018-06-30211,240USD
At 2017-12-31163,088USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2018-06-30834,174USD
At 2017-12-31662,200USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2018-06-304,910,918USD
At 2017-12-313,915,491USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2018-06-301,962,291USD
At 2017-12-311,733,701USD

Current contract liabilities

Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.

PeriodValueUnitDays
At 2017-12-31171,975USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2018-01-01 to 2018-06-30-24,313,567USD181
2017-01-01 to 2017-06-30-15,582,500USD181

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2018-04-01 to 2018-06-30-12,007,233USD91
2018-01-01 to 2018-06-30-24,313,567USD181
2017-04-01 to 2017-06-30-8,323,479USD91
2017-01-01 to 2017-06-30-15,582,500USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2018-04-01 to 2018-06-303,436,340USD91
2018-01-01 to 2018-06-306,856,963USD181
2017-04-01 to 2017-06-302,632,857USD91
2017-01-01 to 2017-06-304,844,650USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2018-04-01 to 2018-06-3021,586USD91
2018-01-01 to 2018-06-3048,152USD181
2017-04-01 to 2017-06-3023,176USD91
2017-01-01 to 2017-06-3043,595USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2018-04-01 to 2018-06-30-37,427USD91
2018-01-01 to 2018-06-3052,375USD181
2017-04-01 to 2017-06-3042,175USD91
2017-01-01 to 2017-06-30486,402USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2018-01-01 to 2018-06-302,921,369USD181
2017-01-01 to 2017-06-30122,445USD181

Inspect the source

Entity
ZYNERBA PHARMACEUTICALS, INC. / CIK 0001621443
Captured
SEC response SHA-256
eb291da6063ca15bb79701a29894e4fddd9d66bcb1e18e0733be9f2efb07eaa3

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001621443.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))